TARRYTOWN, N.Y. - Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN) today revealed positive long-term results from its EYLEA HD clinical program during a series of presentations at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which is scheduled for May 5 to 9 in Seattle.
The data includes one-year outcomes from the PHOTON trial, which studied EYLEA HD in patients with diabetic macular edema (DME), and two-year results from the PULSAR trial in patients with wet age-related macular degeneration (wAMD). Both trials compared the efficacy of EYLEA HD to the standard 2 mg dose of EYLEA.
EYLEA HD, an 8 mg injection, is designed to extend the time between treatments while maintaining similar safety and efficacy as the 2 mg dose. According to the press release, the most common side effects were cataracts, conjunctival hemorrhage, increased intraocular pressure, and blurred vision.
The ARVO presentations will also include a post-hoc analysis of the PULSAR trial, examining the correlation of baseline disease characteristics in wAMD to the dosing intervals of EYLEA HD. Subgroup analyses will evaluate visual and anatomic improvements based on baseline best corrected visual acuity, corneal refractive therapy, choroidal neovascularization type, and race.
Regeneron maintains exclusive rights to EYLEA HD in the U.S., while Bayer (OTC:BAYRY) has licensed exclusive marketing rights outside of the U.S. The companies will equally share profits from sales of EYLEA HD and EYLEA following regulatory approvals.
The PHOTON and PULSAR trials are part of a comprehensive clinical program for EYLEA HD, with the aim of establishing the injection as a new standard-of-care for wAMD, DME, and diabetic retinopathy. The one-year results from these trials were recently published in The Lancet, and the two-year data were presented at major ophthalmology congresses last year.
This news is based on a press release statement from Regeneron Pharmaceuticals, Inc.
InvestingPro Insights
As Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) continues to share promising results from its EYLEA HD clinical program, the company's financial health and stock performance are of particular interest to investors considering the potential impact of new treatments on its market position. Here are the latest insights from InvestingPro:
InvestingPro Data highlights Regeneron's solid financial foundation, with a Market Cap of approximately $95.28 billion and a Price-to-Earnings (P/E) Ratio standing at 21.98 for the last twelve months as of Q4 2023. The company's Gross Profit Margin is robust at 52.32%, indicating efficient operations and a strong ability to generate earnings relative to revenue.
Moreover, InvestingPro Tips suggest that Regeneron's management is confident in the company's future, as evidenced by aggressive share buyback activity. The company holds more cash than debt on its balance sheet, which is a positive sign of financial stability. With 8 analysts having revised their earnings upwards for the upcoming period, there appears to be an optimistic outlook on the company's profitability.
Investors interested in further insights can find additional InvestingPro Tips for Regeneron, including the company's stock trading patterns and industry standing. For those looking to delve deeper, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at https://www.investing.com/pro/REGN. With 12 more InvestingPro Tips available, investors can gain a comprehensive understanding of Regeneron's investment potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.